Kane Biotech Announces Issuance of Restricted Share Units
15 Julio 2024 - 7:30AM
Kane Biotech Inc. (TSX-V:KNE; OTCQB:KNBIF), (the “Company” or “Kane
Biotech”), today announces that it has issued 4,213,133 restricted
share units of the Company (“RSUs”) to various directors, officers,
employees and consultants of the Company pursuant to the third
amended and restated performance and restricted share unit plan of
the Company dated May 22, 2024 (the “PRSU Plan”). Each RSU is
exercisable into one common share of the Company (a “Share”). The
RSUs will vest at different times, but none will vest earlier than
12 months from the date of grant.
On May 22, 2024, at the annual general and
special meeting of shareholders dated May 22, 2024 (the “Meeting”),
the shareholders of the Company approved the PRSU Plan. Under the
PRSU Plan, the Company may issue a maximum of 25,177,198 RSUs,
representing 19% of the issued and outstanding Shares as at the
date of the Meeting.
About Kane Biotech
Kane Biotech Inc. is a biotechnology company
engaged in the research, development and commercialization of
technologies and products that prevent and remove microbial
biofilms. Kane has a portfolio of biotechnologies, intellectual
property (67 patents and patents pending, trade secrets and
trademarks) and products developed by Kane's own biofilm research
expertise and acquired from leading research institutions.
DispersinB®, coactiv+™, coactiv+®, DermaKB™, DermaKB Biofilm™, and
revyve™ are trademarks of Kane Biotech Inc. Kane is listed on the
TSX Venture Exchange under the symbol "KNE" and on the OTCQB
Venture Market under the symbol “KNBIF”.
For more information:
|
|
|
Marc
Edwards |
|
Ray
Dupuis |
Chief Executive Officer |
|
Chief Financial Officer |
Kane Biotech Inc |
|
Kane Biotech Inc |
medwards@kanebiotech.com |
|
rdupuis@kanebiotech.com |
Neither TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Caution Regarding Forward-Looking
InformationThis press release contains certain statements regarding
Kane Biotech Inc. that constitute forward-looking information under
applicable securities law. These statements reflect
management’s current beliefs and are based on information currently
available to management. Certain material factors or assumptions
are applied in making forward-looking statements, and actual
results may differ materially from those expressed or implied in
such statements. These risks and uncertainties include, but are not
limited to, risks relating to Kane’s: (a) financial condition,
including lack of significant revenues to date and reliance on
equity and other financing; (b) business, including its early stage
of development, government regulation, market acceptance for its
products, rapid technological change and dependence on key
personnel; (c) intellectual property including the ability of Kane
to protect its intellectual property and dependence on its
strategic partners; and (d) capital structure, including its lack
of dividends on its common shares, volatility of the market price
of its common shares and public company costs. Further information
about these and other risks and uncertainties can be found in the
disclosure documents filed by Kane with applicable securities
regulatory authorities, available at www.sedarplus.ca. Kane
cautions that the foregoing list of factors that may affect future
results is not exhaustive.
Kane Biotech (TSXV:KNE)
Gráfica de Acción Histórica
De Jul 2024 a Ago 2024
Kane Biotech (TSXV:KNE)
Gráfica de Acción Histórica
De Ago 2023 a Ago 2024